Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR NK Cells in Relapsed/Refractory B-Cell Lymphoma
NCT03692767Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of anti-CD22 CAR NK cells in B cell lymphoma, sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events. Status: unknown.
02
Drugs
anti-CD22 CAR NK cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03692767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692767.